Cigna (CI) Q2 Revenue Jumps 11%

01.08.25 23:33 Uhr

Werte in diesem Artikel
Aktien

62,00 EUR -2,50 EUR -3,88%

244,00 EUR -1,75 EUR -0,71%

Indizes

6.604,7 PKT -33,3 PKT -0,50%

Cigna Group (NYSE:CI), a global health services company offering integrated medical, pharmacy, and specialty care solutions, released its second-quarter earnings on July 31, 2025. The company reported headline financial results (non-GAAP) that outpaced analyst expectations, with revenue climbed to $67.2 billion and adjusted diluted EPS was $7.20. Analysts had expected adjusted EPS (non-GAAP) of $7.16 and revenue of $62,571.45 million. The quarter featured broad-based revenue growth, driven by the Evernorth Health Services platform, though overall profit margins moderated and the company faced shifts in customer mix due to the divestiture of Medicare-related businesses. Overall, the period showed strong execution and ongoing investment in innovation across the enterprise. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Cigna Group is organized around two primary business platforms: Evernorth Health Services, which provides pharmacy benefit services and specialty care, and Cigna Healthcare, which offers medical insurance plans in the U.S. and globally. By leveraging both platforms, the company aims to deliver integrated solutions across medical, pharmacy, and specialty categories. This dual-structure enables it to address the unique needs of diverse customer groups, from large employers to individual members.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Q2

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q2

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: MotleyFool

Nachrichten zu The Cigna Group Registered Shs

Wer­bung

Analysen zu The Cigna Group Registered Shs

DatumRatingAnalyst
20.07.2018Express Scripts NeutralRobert W. Baird & Co. Incorporated
08.03.2018Express Scripts Equal WeightBarclays Capital
08.03.2018Cigna OverweightBarclays Capital
31.01.2018Express Scripts OutperformRBC Capital Markets
15.12.2017Express Scripts OutperformRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
08.03.2018Cigna OverweightBarclays Capital
31.01.2018Express Scripts OutperformRBC Capital Markets
15.12.2017Express Scripts OutperformRobert W. Baird & Co. Incorporated
14.12.2017Express Scripts BuyMaxim Group
04.12.2017Express Scripts BuyDeutsche Bank AG
DatumRatingAnalyst
20.07.2018Express Scripts NeutralRobert W. Baird & Co. Incorporated
08.03.2018Express Scripts Equal WeightBarclays Capital
19.09.2017Express Scripts Sector PerformRBC Capital Markets
21.07.2017Express Scripts HoldNeedham & Company, LLC
26.04.2017Express Scripts HoldEdward Jones
DatumRatingAnalyst
22.02.2016Express Scripts SellDeutsche Bank AG
13.01.2009CIGNA sellCitigroup Corp.
07.11.2007CIGNA underweightLehman Brothers Inc.
02.11.2006Update CIGNA Corp.: UnderweightLehman Brothers

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für The Cigna Group Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen